Bortezomib reinduction chemotherapy in high‐risk ALL in first relapse: a report from the Children's Oncology Group

Summary While survival in paediatric acute lymphoblastic leukaemia (ALL) is excellent, survival following relapse is poor. Previous studies suggest proteasome inhibition with chemotherapy improves relapse ALL response rates. This phase 2 Children's Oncology Group study tested the hypothesis tha...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	British journal of haematology Ročník 186; číslo 2; s. 274 - 285
Hlavní autoři:	Horton, Terzah M., Whitlock, James A., Lu, Xiaomin, O'Brien, Maureen M., Borowitz, Michael J., Devidas, Meenakshi, Raetz, Elizabeth A., Brown, Patrick A., Carroll, William L., Hunger, Stephen P.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Blackwell Publishing Ltd 01.07.2019
Témata:	acute lymphoblastic leukaemia Acute lymphoblastic leukemia acute lymphocytic leukaemia Adolescent Adult Bortezomib Bortezomib - administration & dosage Bortezomib - adverse effects Chemotherapy Child Child, Preschool Children Clinical trials Diagnosis Disease-Free Survival Female Hematology Humans Infant Leukemia Lymphoma Male Minimal residual disease Neoplasm, Residual Oncology paediatric leukaemia Precursor Cell Lymphoblastic Leukemia-Lymphoma - blood Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality proteasome inhibition Proteasome inhibitors Recurrence Survival Rate Time Factors proteasome inhibition acute lymphocytic leukaemia minimal residual disease acute lymphoblastic leukaemia paediatric leukaemia
ISSN:	0007-1048, 1365-2141, 1365-2141
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!